AIMS: In the SCALAF trial, catheter-based pulmonary vein isolation (PVI) was as effective in long-term prevention of atrial fibrillation (AF) as minimally invasive thoracoscopic PVI and left atrial appendage ligation (MIPI). Catheter ablation (CA) resulted in significantly less major complications as compare to MIPI. We report quality of life (QOL) outcome in these patients. METHODS: In this study, 52 patients with symptomatic paroxysmal or early persistent AF were randomized to either MIPI or CA. QOL was assessed at baseline, 3, 6, and 12 months follow-up using the SF-36 Health Survey Questionnaire. AF-related symptoms were quantified at each follow-up visit using the European Heart Rhythm Association (EHRA) score. RESULTS: Median age was 57 years and 78% was male. Paroxysmal AF was present in 74%. At 3 months follow-up, physical role limitations (88.2 ± 29.5; versus 40.9 ± 44.0; P = 0.001, respectively) and bodily pain scores (95.5 ± 8.7; versus 76.0 ± 27.8; P = 0.021, respectively) were significantly higher after CA compared to MIPI, indicating less limitation in daily activity caused by physical problems and less pain after CA than after MIPI. AF symptoms assessed by the EHRA scores improved significantly at 3, 6, 12, and 24 months compared to baseline in both treatment groups (P < 0.001), with no significant differences between treatment groups. CONCLUSIONS: CA and MIPI ablation of AF both resulted in an improvement in several QOL measurements, although CA resulted in significantly less physical problems and bodily pain 3 months after treatment compared to MIPI. CLINICAL TRIAL NUMBER: ClinicalTrials.gov identifier: NCT00703157.
AIMS: In the SCALAF trial, catheter-based pulmonary vein isolation (PVI) was as effective in long-term prevention of atrial fibrillation (AF) as minimally invasive thoracoscopic PVI and left atrial appendage ligation (MIPI). Catheter ablation (CA) resulted in significantly less major complications as compare to MIPI. We report quality of life (QOL) outcome in these patients. METHODS: In this study, 52 patients with symptomatic paroxysmal or early persistent AF were randomized to either MIPI or CA. QOL was assessed at baseline, 3, 6, and 12 months follow-up using the SF-36 Health Survey Questionnaire. AF-related symptoms were quantified at each follow-up visit using the European Heart Rhythm Association (EHRA) score. RESULTS: Median age was 57 years and 78% was male. Paroxysmal AF was present in 74%. At 3 months follow-up, physical role limitations (88.2 ± 29.5; versus 40.9 ± 44.0; P = 0.001, respectively) and bodily pain scores (95.5 ± 8.7; versus 76.0 ± 27.8; P = 0.021, respectively) were significantly higher after CA compared to MIPI, indicating less limitation in daily activity caused by physical problems and less pain after CA than after MIPI. AF symptoms assessed by the EHRA scores improved significantly at 3, 6, 12, and 24 months compared to baseline in both treatment groups (P < 0.001), with no significant differences between treatment groups. CONCLUSIONS: CA and MIPI ablation of AF both resulted in an improvement in several QOL measurements, although CA resulted in significantly less physical problems and bodily pain 3 months after treatment compared to MIPI. CLINICAL TRIAL NUMBER: ClinicalTrials.gov identifier: NCT00703157.
Entities:
Keywords:
Atrial fibrillation; Catheter ablation; Minimally invasive surgery; Quality of life
Authors: Lucas V A Boersma; Manuel Castella; Wimjan van Boven; Antonio Berruezo; Alaaddin Yilmaz; Mercedes Nadal; Elena Sandoval; Naiara Calvo; Josep Brugada; Johannes Kelder; Maurits Wijffels; Lluís Mont Journal: Circulation Date: 2011-11-14 Impact factor: 29.690
Authors: Ahmet Adiyaman; Thomas J Buist; Rypko J Beukema; Jaap Jan J Smit; Peter Paul H M Delnoy; Martin E W Hemels; Hauw T Sie; Anand R Ramdat Misier; Arif Elvan Journal: Circ Arrhythm Electrophysiol Date: 2018-10
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin Journal: Circulation Date: 2003-05-27 Impact factor: 29.690
Authors: Konstantinos C Siontis; John P A Ioannidis; George D Katritsis; Peter A Noseworthy; Douglas L Packer; John D Hummel; Pierre Jais; Rungroj Krittayaphong; Llius Mont; Carlos A Morillo; Jens Cosedis Nielsen; Hakan Oral; Carlo Pappone; Vincenzo Santinelli; Rukshen Weerasooriya; David J Wilber; Bernard J Gersh; Mark E Josephson; Demosthenes G Katritsis Journal: JACC Clin Electrophysiol Date: 2015-11-10
Authors: Douglas L Packer; Daniel B Mark; Richard A Robb; Kristi H Monahan; Tristram D Bahnson; Jeanne E Poole; Peter A Noseworthy; Yves D Rosenberg; Neal Jeffries; L Brent Mitchell; Greg C Flaker; Evgeny Pokushalov; Alexander Romanov; T Jared Bunch; Georg Noelker; Andrey Ardashev; Amiran Revishvili; David J Wilber; Riccardo Cappato; Karl-Heinz Kuck; Gerhard Hindricks; D Wyn Davies; Peter R Kowey; Gerald V Naccarelli; James A Reiffel; Jonathan P Piccini; Adam P Silverstein; Hussein R Al-Khalidi; Kerry L Lee Journal: JAMA Date: 2019-04-02 Impact factor: 56.272
Authors: Simon G Anderson; Ahmad Shoaib; Phyo Kyaw Myint; John G Cleland; Suzanna M Hardman; Theresa A McDonagh; Henry Dargie; Bernard Keavney; Clifford J Garratt; Mamas A Mamas Journal: Clin Res Cardiol Date: 2019-04-08 Impact factor: 5.460
Authors: Bart Maesen; Claudia A J van der Heijden; Elham Bidar; Rein Vos; Thanos Athanasiou; Jos G Maessen Journal: Interact Cardiovasc Thorac Surg Date: 2022-02-21
Authors: Ann-Kathrin Rahm; Patrick Lugenbiel; Marco Ochs; Benjamin Meder; Dierk Thomas; Hugo A Katus; Eberhard Scholz Journal: Clin Res Cardiol Date: 2020-03-06 Impact factor: 5.460